1. |
Suri HS, Yi ES, Nowakowski GS, et al. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis, 2012, 7: 16.
|
2. |
Mourah S, How-Kit A, Meignin V, et al. Recurrent NRAS mutations in pulmonary langerhans cell histiocytosis. Eur Respir J, 2016, 47(6): 1785-1796.
|
3. |
Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood, 2020, 135(16): 1319-1331.
|
4. |
Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med, 2018, 379(9): 856-868.
|
5. |
Goyal G, Young JR, Koster MJ, et al. The Mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc, 2019, 94(10): 2054-2071.
|
6. |
Kumar A, Cherian SV, Vassallo R, et al. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest, 2018, 154(2): 394-408.
|
7. |
Lorillon G, Tazi A. How I manage pulmonary langerhans cell histiocytosis. Eur Respir Rev, 2017, 26(145): 170070.
|
8. |
许秦风, 郭万华. 肺朗格汉斯细胞组织细胞增生症的高分辨率CT及18F-FDG PET/CT表现. 中国医学影像学杂志, 2016, 24(10): 741-745.
|
9. |
Obert J, Vercellino L, Van Der Gucht A, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging, 2017, 44(4): 598-610.
|
10. |
Hazim AZ, Ruan GJ, Ravindran A, et al. Efficacy of BRAF-inhibitor therapy in BRAFV600E-mutated adult Langerhans cell histiocytosis. Oncologist, 2020, 25(12): 1001-1004.
|